Zobrazeno 1 - 10
of 52
pro vyhledávání: '"Jennifer L. Caswell"'
Autor:
Kaitlyn M. Wojcik, Jennifer L. Caswell-Jin, Oliver W.A. Wilson, Clyde Schechter, Dalya Kamil, Allison W. Kurian, Jinani Jayasekera
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-11 (2024)
Abstract Background A recent trial showed that postmenopausal women diagnosed with hormone receptor-positive, human epidermal growth factor receptor-2 (HER2)-negative, lymph node-positive (1–3 nodes) breast cancer with a 21-gene recurrence score of
Externí odkaz:
https://doaj.org/article/6e4a681ff6304a3e8484d2440c03c8b2
Autor:
Sara A. Hurvitz, Jennifer L. Caswell-Jin, Katherine L. McNamara, Jason J. Zoeller, Gregory R. Bean, Robert Dichmann, Alejandra Perez, Ravindranath Patel, Lee Zehngebot, Heather Allen, Linda Bosserman, Brian DiCarlo, April Kennedy, Armando Giuliano, Carmen Calfa, David Molthrop, Aruna Mani, Hsiao-Wang Chen, Judy Dering, Brad Adams, Eran Kotler, Michael F. Press, Joan S. Brugge, Christina Curtis, Dennis J. Slamon
Publikováno v:
Nature Communications, Vol 11, Iss 1, Pp 1-15 (2020)
HER2+ breast cancer patients can often develop resistance to trastuzumab and therefore potential combination therapies need to be explored. Here, the authors report the results of a multi-center randomized phase II clinical trial evaluating the patho
Externí odkaz:
https://doaj.org/article/3ed71c9a08f44623be4704bf23a0df55
Clonal replacement and heterogeneity in breast tumors treated with neoadjuvant HER2-targeted therapy
Autor:
Jennifer L. Caswell-Jin, Katherine McNamara, Johannes G. Reiter, Ruping Sun, Zheng Hu, Zhicheng Ma, Jie Ding, Carlos J. Suarez, Susanne Tilk, Akshara Raghavendra, Victoria Forte, Suet-Feung Chin, Helen Bardwell, Elena Provenzano, Carlos Caldas, Julie Lang, Robert West, Debu Tripathy, Michael F. Press, Christina Curtis
Publikováno v:
Nature Communications, Vol 10, Iss 1, Pp 1-12 (2019)
When examining the evolution of treatment resistance in breast cancer, perceived genomic changes may be due to clonal evolution or heterogeneous tumors. Here, the authors show that apparent clonal change can in fact be due to pre-treatment heterogene
Externí odkaz:
https://doaj.org/article/3b5c30a996d54c2086cfff5a285a1014
Autor:
Jennifer L. Caswell-Jin, Katherine McNamara, Johannes G. Reiter, Ruping Sun, Zheng Hu, Zhicheng Ma, Jie Ding, Carlos J. Suarez, Susanne Tilk, Akshara Raghavendra, Victoria Forte, Suet-Feung Chin, Helen Bardwell, Elena Provenzano, Carlos Caldas, Julie Lang, Robert West, Debu Tripathy, Michael F. Press, Christina Curtis
Publikováno v:
Nature Communications, Vol 10, Iss 1, Pp 1-1 (2019)
The original version of this Article omitted from the Author Contributions statement that ‘R.S. and J.G.R contributed equally to this work.’ This has been corrected in both the PDF and HTML versions of the Article.
Externí odkaz:
https://doaj.org/article/b021138f6e9b4cb1925f14aab5f161ba
Autor:
Jennifer L. Caswell-Jin, Maryam N. Shafaee, Lan Xiao, Mina Liu, Esther M. John, Melissa L. Bondy, Allison W. Kurian
Publikováno v:
Breast Cancer Research and Treatment. 194:475-482
The early months of the COVID-19 pandemic led to reduced cancer screenings and delayed cancer surgeries. We used insurance claims data to understand how breast cancer incidence and treatment after diagnosis changed nationwide over the course of the p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f8d83257d33fa9b59ab51b48edc5d73
https://doi.org/10.1007/s10549-022-06634-z
https://doi.org/10.1007/s10549-022-06634-z
Autor:
Divya A. Parikh, Lisa Kody, Susie Brain, Diane Heditsian, Vivian Lee, Christina Curtis, Mardi R. Karin, Irene L. Wapnir, Manali I. Patel, George W. Sledge, Jennifer L. Caswell-Jin
Publikováno v:
Breast Cancer Research and Treatment. 194:171-178
Window of opportunity trials (WOT) are increasingly common in oncology research. In WOT participants receive a drug between diagnosis and anti-cancer treatment, usually for the purpose of investigating that drugs effect on cancer biology. This qualit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0fc65bebcab0d879f26e14d74ee92b6b
https://doi.org/10.1007/s10549-022-06611-6
https://doi.org/10.1007/s10549-022-06611-6
Autor:
Jennifer L Caswell-Jin, Maryam N Shafaee, Lan Xiao, Mina Liu, Natasha Purington, Esther M John, Melissa L Bondy, Allison W Kurian
Publikováno v:
Cancer Research. 82:P5-14
Background: The COVID-19 pandemic imposed great burden on the healthcare system and has required patients and their physicians to make unprecedented choices about cancer care. Hospital-based retrospective reviews have suggested changes in breast canc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bf94a1af103f61dee142b33ccbc02401
https://doi.org/10.1158/1538-7445.sabcs21-p5-14-01
https://doi.org/10.1158/1538-7445.sabcs21-p5-14-01
Autor:
Gregory R. Bean, Saleh Najjar, Sandra J. Shin, Elizabeth M. Hosfield, Jennifer L. Caswell-Jin, Anatoly Urisman, Kirk D. Jones, Yunn-Yi Chen, Gregor Krings
Publikováno v:
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, vol 35, iss 10
Neuroendocrine carcinomas (NEC) of the breast are exceedingly rare tumors, which are classified in the WHO system as small cell (SCNEC) and large cell (LCNEC) carcinoma based on indistinguishable features from their lung counterparts. In contrast to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9e058f8d3fec873a1403c304ea8371d6
https://escholarship.org/uc/item/14p3p8g1
https://escholarship.org/uc/item/14p3p8g1
Autor:
Susanne Wagner, Alexander Gutin, Allison W. Kurian, Ryan Bernhisel, Stephanie Meek, Esther M. John, Thomas P. Slavin, JoAnn E. Manson, Aladdin H. Shadyab, Jennifer L. Caswell-Jin, Thomas E. Rohan, Braden Probst, Jerry S. Lanchbury, Dorothy S. Lane, Elisha Hughes, Timothy Simmons, Marcia L. Stefanick, Rowan T. Chlebowski
Publikováno v:
Cancer. 127:3742-3750
BACKGROUND The IBIS/Tyrer-Cuzick model is used clinically to guide breast cancer screening and prevention, but was developed primarily in non-Hispanic White women. Little is known about its long-term performance in a racially/ethnically diverse popul
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8207acc83d2a0684b45cd9a82818d544
https://doi.org/10.1002/cncr.33767
https://doi.org/10.1002/cncr.33767
Autor:
Rohan P. Joshi, Michael F. Press, Jennifer L. Caswell-Jin, Michelle Kriner, Zhicheng Ma, Joseph M. Beechem, Zoey Zhou, Gregory R. Bean, Margaret L. Hoang, Dennis J. Slamon, Jason J. Zoeller, Sara A. Hurvitz, Eran Kotler, Katherine McNamara, Christina Curtis
Publikováno v:
Nature cancer, vol 2, iss 4
Nat Cancer
Nat Cancer
Addition of HER2-targeted agents to neoadjuvant chemotherapy has dramatically improved pathological complete response (pCR) rates in early stage Human epidermal growth factor receptor 2 (HER2)-positive breast cancer. Still, up to 50% of patients have
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f77f4da583c6954b7546756210ee9b65
https://doi.org/10.1038/s43018-021-00190-z
https://doi.org/10.1038/s43018-021-00190-z